Frank C Bandiera1, Kathryn C Ross1, Seyedehtaraneh Taghavi2, Kevin Delucchi3, Rachel F Tyndale4, Neal L Benowitz5. 1. Center for Tobacco Control Research and Education, School of Medicine, University of California, San Francisco, CA; 2. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; 3. Department of Psychiatry, University of California, San Francisco, CA; 4. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 5. Center for Tobacco Control Research and Education, School of Medicine, University of California, San Francisco, CA; Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, Departments of Medicine, Bioengineering and Therapeutic Sciences and the Center for Tobacco Control Research and Education, University of California, San Francisco, CA neal.benowitz@ucsf.edu.
Abstract
INTRODUCTION: The Food and Drug Administration has the authority to regulate tobacco product constituents, including nicotine, to promote public health. Reducing the nicotine content in cigarettes may lead to lower levels of addiction. Smokers however may compensate by smoking more cigarettes and/or smoking more intensely. The objective of this study was to test whether individual differences in the level of nicotine dependence (as measured by the Fagerstrom Test of Cigarette Dependence [FTCD]) and/or the rate of nicotine metabolism influence smoking behavior and exposure to tobacco toxicants when smokers are switched to reduced nicotine content cigarettes (RNC). METHODS: Data from 51 participants from a previously published clinical trial of RNC were analyzed. Nicotine content of cigarettes was progressively reduced over 6 months and measures of smoking behavior, as well as nicotine metabolites and tobacco smoke toxicant exposure, CYP2A6 and nicotinic CHRNA5-A3-B4 (rs1051730) genotype were measured. RESULTS: Higher baseline FTCD predicted smoking more cigarettes per day (CPD), higher cotinine and smoke toxicant levels while smoking RNC throughout the study, with no interaction by RNC level. Time to first cigarette (TFC) was associated with differences in compensation. TFC within 10 min was associated with a greater increase in CPD compared to TFC greater than 10 min. Neither rate of nicotine metabolism, nor CYP2A6 or nicotinic receptor genotype, had an effect on the outcome variables of interest. CONCLUSIONS:FTCD is associated with overall exposure to nicotine and other constituents of tobacco smoke, while a short TFC is associated with an increased compensatory response after switching to RNC.
RCT Entities:
INTRODUCTION: The Food and Drug Administration has the authority to regulate tobacco product constituents, including nicotine, to promote public health. Reducing the nicotine content in cigarettes may lead to lower levels of addiction. Smokers however may compensate by smoking more cigarettes and/or smoking more intensely. The objective of this study was to test whether individual differences in the level of nicotine dependence (as measured by the Fagerstrom Test of Cigarette Dependence [FTCD]) and/or the rate of nicotine metabolism influence smoking behavior and exposure to tobacco toxicants when smokers are switched to reduced nicotine content cigarettes (RNC). METHODS: Data from 51 participants from a previously published clinical trial of RNC were analyzed. Nicotine content of cigarettes was progressively reduced over 6 months and measures of smoking behavior, as well as nicotine metabolites and tobacco smoke toxicant exposure, CYP2A6 and nicotinic CHRNA5-A3-B4 (rs1051730) genotype were measured. RESULTS: Higher baseline FTCD predicted smoking more cigarettes per day (CPD), higher cotinine and smoke toxicant levels while smoking RNC throughout the study, with no interaction by RNC level. Time to first cigarette (TFC) was associated with differences in compensation. TFC within 10 min was associated with a greater increase in CPD compared to TFC greater than 10 min. Neither rate of nicotine metabolism, nor CYP2A6 or nicotinic receptor genotype, had an effect on the outcome variables of interest. CONCLUSIONS: FTCD is associated with overall exposure to nicotine and other constituents of tobacco smoke, while a short TFC is associated with an increased compensatory response after switching to RNC.
Authors: Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale Journal: Clin Pharmacol Ther Date: 2006-11 Impact factor: 6.875
Authors: Thorgeir E Thorgeirsson; Frank Geller; Patrick Sulem; Thorunn Rafnar; Anna Wiste; Kristinn P Magnusson; Andrei Manolescu; Gudmar Thorleifsson; Hreinn Stefansson; Andres Ingason; Simon N Stacey; Jon T Bergthorsson; Steinunn Thorlacius; Julius Gudmundsson; Thorlakur Jonsson; Margret Jakobsdottir; Jona Saemundsdottir; Olof Olafsdottir; Larus J Gudmundsson; Gyda Bjornsdottir; Kristleifur Kristjansson; Halla Skuladottir; Helgi J Isaksson; Tomas Gudbjartsson; Gregory T Jones; Thomas Mueller; Anders Gottsäter; Andrea Flex; Katja K H Aben; Femmie de Vegt; Peter F A Mulders; Dolores Isla; Maria J Vidal; Laura Asin; Berta Saez; Laura Murillo; Thorsteinn Blondal; Halldor Kolbeinsson; Jon G Stefansson; Ingunn Hansdottir; Valgerdur Runarsdottir; Roberto Pola; Bengt Lindblad; Andre M van Rij; Benjamin Dieplinger; Meinhard Haltmayer; Jose I Mayordomo; Lambertus A Kiemeney; Stefan E Matthiasson; Hogni Oskarsson; Thorarinn Tyrfingsson; Daniel F Gudbjartsson; Jeffrey R Gulcher; Steinn Jonsson; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: Nature Date: 2008-04-03 Impact factor: 49.962
Authors: Neal L Benowitz; Sharon M Hall; Susan Stewart; Margaret Wilson; Delia Dempsey; Peyton Jacob Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11 Impact factor: 4.254
Authors: Timothy B Baker; Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Su-Young Kim; Suzanne Colby; David Conti; Gary A Giovino; Dorothy Hatsukami; Andrew Hyland; Suchitra Krishnan-Sarin; Raymond Niaura; Kenneth A Perkins; Benjamin A Toll Journal: Nicotine Tob Res Date: 2007-11 Impact factor: 4.244
Authors: Melissa Mercincavage; Megan L Saddleson; Emily Gup; Angela Halstead; Darren Mays; Andrew A Strasser Journal: Drug Alcohol Depend Date: 2017-02-03 Impact factor: 4.492
Authors: Patricia E Grebenstein; Danielle Burroughs; Samuel A Roiko; Paul R Pentel; Mark G LeSage Journal: Drug Alcohol Depend Date: 2015-04-07 Impact factor: 4.492
Authors: Tracy T Smith; Laura E Rupprecht; Rachel L Denlinger-Apte; Jillian J Weeks; Rachel S Panas; Eric C Donny; Alan F Sved Journal: Nicotine Tob Res Date: 2017-09-01 Impact factor: 4.244
Authors: Paul Faulkner; Dara G Ghahremani; Rachel F Tyndale; Chelsea M Cox; Ari S Kazanjian; Neil Paterson; Shahrdad Lotfipour; Gerhard S Hellemann; Nicole Petersen; Celia Vigil; Edythe D London Journal: Neuropsychopharmacology Date: 2017-01-24 Impact factor: 7.853
Authors: Melissa Mercincavage; Kirsten Lochbuehler; E Paul Wileyto; Neal L Benowitz; Rachel F Tyndale; Caryn Lerman; Andrew A Strasser Journal: JAMA Netw Open Date: 2018-08-24
Authors: Nicole Kuiper; Ellen M Coats; Tamara N Crawford; Doris G Gammon; Brett Loomis; Clifford H Watson; Paul C Melstrom; Rene Lavinghouze; Todd Rogers; Brian A King Journal: Prev Chronic Dis Date: 2020-11-25 Impact factor: 2.830